Insulin-Like Growth Factor 1 Receptor as a Therapeutic Target in Ewing Sarcoma : Lack of Consistent Upregulation or Recurrent Mutation and a Review of the Clinical Trial Literature
المؤلفون المشاركون
Zitomersky, Naamah
Loeb, David
O'Neill, Alison
Ladanyi, Marc
Üren, Aykut
Shah, Nilay
Shukla, Neerav
Toretsky, Jeffrey
المصدر
العدد
المجلد 2013، العدد 2013 (31 ديسمبر/كانون الأول 2013)، ص ص. 1-12، 12ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2013-01-28
دولة النشر
مصر
عدد الصفحات
12
التخصصات الرئيسية
الملخص EN
The insulin-like growth factor 1 receptor (IGF-1R) has been considered an important therapeutic target in Ewing sarcoma (ES), generating a need to identify the subset of patients most likely to respond to IGF-1R inhibitors.
We assessed IGF-1R expression in ES cell lines and patient tumors to understand the variable clinical responses to anti-IGF-1R therapy.
Using ligand-binding displacement, we measured between 13,000 and 40,000 receptors per cell in ES cell lines.
We used ELISA to quantify IGF-1R in patient tumors, which expressed 4.8% ± 3.7 to 20.0% ± 0.2 of the levels in a positive control cell line overexpressing IGF-1R.
Flow cytometry showed markedly reduced IGF-1R expression in ES cell lines compared to a standard positive control cell line.
The IGF1R gene was sequenced in 47 ES tumor samples and 8 ES cell lines; only one tumor sample showed a nonsynonymous mutation, R1353H, in a region with low functional impact.
Finally, we assessed IGF-1R pathway activity in the ES stem cell (ESSC) population, to characterize its potential for resistance to anti-IGF-1R therapy, using Luminex technology.
We found no significant differences in IGF-1R pathway activity between ESSCs and the total cell population.
Overall, our findings suggest that IGF-1R as a therapeutic target in this sarcoma may require reevaluation.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
O'Neill, Alison& Shah, Nilay& Zitomersky, Naamah& Ladanyi, Marc& Shukla, Neerav& Üren, Aykut…[et al.]. 2013. Insulin-Like Growth Factor 1 Receptor as a Therapeutic Target in Ewing Sarcoma : Lack of Consistent Upregulation or Recurrent Mutation and a Review of the Clinical Trial Literature. Sarcoma،Vol. 2013, no. 2013, pp.1-12.
https://search.emarefa.net/detail/BIM-472546
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
O'Neill, Alison…[et al.]. Insulin-Like Growth Factor 1 Receptor as a Therapeutic Target in Ewing Sarcoma : Lack of Consistent Upregulation or Recurrent Mutation and a Review of the Clinical Trial Literature. Sarcoma No. 2013 (2013), pp.1-12.
https://search.emarefa.net/detail/BIM-472546
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
O'Neill, Alison& Shah, Nilay& Zitomersky, Naamah& Ladanyi, Marc& Shukla, Neerav& Üren, Aykut…[et al.]. Insulin-Like Growth Factor 1 Receptor as a Therapeutic Target in Ewing Sarcoma : Lack of Consistent Upregulation or Recurrent Mutation and a Review of the Clinical Trial Literature. Sarcoma. 2013. Vol. 2013, no. 2013, pp.1-12.
https://search.emarefa.net/detail/BIM-472546
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-472546
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر